These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1977544)

  • 1. Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics.
    Ereshefsky L; Tran-Johnson TK; Watanabe MD
    Clin Pharm; 1990 Sep; 9(9):682-707. PubMed ID: 1977544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
    Jann MW
    Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G; Chong SA
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
    Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine].
    Gosselin O; Ribeyre JM; Kahn JP
    Encephale; 1997 Sep; 23 Spec No 4():2-6. PubMed ID: 9417400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of schizophrenia and the role of newer antipsychotics.
    Risch SC
    Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The chances of new atypical substances].
    Falkai P; Vogeley K
    Fortschr Neurol Psychiatr; 2000 Apr; 68 Suppl 1():S32-7. PubMed ID: 10907611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The mechanisms of action of antipsychotic drugs: is atypicality superior in schizophrenia treatment?].
    Anil Yağcioğlu AE
    Turk Psikiyatri Derg; 2007; 18(4):364-74. PubMed ID: 18066727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain.
    Advokat C
    Essent Psychopharmacol; 2005; 6(2):73-90. PubMed ID: 15765792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.